ICER plans to assess the comparative clinical effectiveness and value of LentiGlobin (Bluebird Bio) and luspatercept-aamt (Reblozyl®, Bristol Myers Squib and Celgene) for the treatment of beta thalassemia. LentiGlobin is an investigational gene therapy currently marketed in Europe under the brand name Zynteglo®; an FDA decision regarding potential US approval is expected by late 2020. Luspatercept-aamt was approved by the FDA in November 2019.
Date of Review: July 2020
For questions, please contact Catherine Koola, Program Manager, at firstname.lastname@example.org.